Quest Diagnostics (DGX) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Quest Diagnostics (DGX) Upgraded to Buy: Here's Why
Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Quest Diagnostics Stock a Right Pick for Your Portfolio Now?
DGX banks on acquisitions, advanced diagnostics and cost discipline, even as debt levels and macro pressures pose risks.
Is Quest Diagnostics (DGX) Stock Outpacing Its Medical Peers This Year?
Here is how Quest Diagnostics (DGX) and Elicio Therapeutics (ELTX) have performed compared to their sector so far this year.
Here's Why Quest Diagnostics (DGX) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Should You Hold Quest Diagnostics Stock in Your Portfolio for Now?
DGX pushes growth through acquisitions and advanced diagnostics even as rising debt and tough competition pressure its outlook.
Quest Diagnostics (DGX) Up 2.6% Since Last Earnings Report: Can It Continue?
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?
Quest Diagnostics Incorporated (DGX) Presents at 7th Annual Healthcare Symposium Transcript
Quest Diagnostics Incorporated ( DGX ) 7th Annual Healthcare Symposium November 14, 2025 8:50 AM EST Company Participants Asia Chang Conference Call Participants Kevin Dreyer - GAMCO Investors, Inc. Carri Chan David Harding Noam Krantz - Guardant Health, Inc. Alexis Tosti Presentation Kevin Dreyer GAMCO Investors, Inc. Okay. I want to welcome everyone to our 7th Annual Healthcare Symposium jointly sponsored by Gabelli Funds and Columbia Business School.
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Quest Diagnostics (DGX) is a Top-Ranked Growth Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
